243 related articles for article (PubMed ID: 32871137)
1. Thienorphine induces antinociception without dependence through activation of κ- and δ-, and partial activation of μ- opioid receptor.
Zhou P; Li Y; Yong Z; Chen M; Zhang Y; Su R; Gong Z
Brain Res; 2020 Dec; 1748():147083. PubMed ID: 32871137
[TBL] [Abstract][Full Text] [Related]
2. Buprenorphine antinociception is abolished, but naloxone-sensitive reward is retained, in mu-opioid receptor knockout mice.
Ide S; Minami M; Satoh M; Uhl GR; Sora I; Ikeda K
Neuropsychopharmacology; 2004 Sep; 29(9):1656-63. PubMed ID: 15100703
[TBL] [Abstract][Full Text] [Related]
3. Morphine can produce analgesia via spinal kappa opioid receptors in the absence of mu opioid receptors.
Yamada H; Shimoyama N; Sora I; Uhl GR; Fukuda Y; Moriya H; Shimoyama M
Brain Res; 2006 Apr; 1083(1):61-9. PubMed ID: 16530171
[TBL] [Abstract][Full Text] [Related]
4. HS-599: a novel long acting opioid analgesic does not induce place-preference in rats.
Lattanzi R; Negri L; Giannini E; Schmidhammer H; Schutz J; Improta G
Br J Pharmacol; 2001 Sep; 134(2):441-7. PubMed ID: 11564664
[TBL] [Abstract][Full Text] [Related]
5. Abolished thermal and mechanical antinociception but retained visceral chemical antinociception induced by butorphanol in mu-opioid receptor knockout mice.
Ide S; Minami M; Ishihara K; Uhl GR; Satoh M; Sora I; Ikeda K
Neuropharmacology; 2008 Jun; 54(8):1182-8. PubMed ID: 18417173
[TBL] [Abstract][Full Text] [Related]
6. Activation of delta-opioid receptor contributes to the antinociceptive effect of oxycodone in mice.
Yang PP; Yeh GC; Yeh TK; Xi J; Loh HH; Law PY; Tao PL
Pharmacol Res; 2016 Sep; 111():867-876. PubMed ID: 27496654
[TBL] [Abstract][Full Text] [Related]
7. mu/delta Cooperativity and opposing kappa-opioid effects in nucleus accumbens-mediated antinociception in the rat.
Schmidt BL; Tambeli CH; Levine JD; Gear RW
Eur J Neurosci; 2002 Mar; 15(5):861-8. PubMed ID: 11906528
[TBL] [Abstract][Full Text] [Related]
8. Antinociceptive activity of a novel buprenorphine analogue.
Lattanzi R; Negri L; Schmidhammer H; Giannini E
Life Sci; 2002 Mar; 70(18):2177-85. PubMed ID: 12002809
[TBL] [Abstract][Full Text] [Related]
9. Nociceptin/orphanin FQ receptor activation attenuates antinociception induced by mixed nociceptin/orphanin FQ/mu-opioid receptor agonists.
Khroyan TV; Polgar WE; Jiang F; Zaveri NT; Toll L
J Pharmacol Exp Ther; 2009 Dec; 331(3):946-53. PubMed ID: 19713488
[TBL] [Abstract][Full Text] [Related]
10. Antinociceptive effects of the 6-O-sulfate ester of morphine in normal and diabetic rats: Comparative role of mu- and delta-opioid receptors.
Yadlapalli JSK; Ford BM; Ketkar A; Wan A; Penthala NR; Eoff RL; Prather PL; Dobretsov M; Crooks PA
Pharmacol Res; 2016 Nov; 113(Pt A):335-347. PubMed ID: 27637375
[TBL] [Abstract][Full Text] [Related]
11. Thienorphine: receptor binding and behavioral effects in rhesus monkeys.
Li JX; Becker GL; Traynor JR; Gong ZH; France CP
J Pharmacol Exp Ther; 2007 Apr; 321(1):227-36. PubMed ID: 17220427
[TBL] [Abstract][Full Text] [Related]
12. Buprenorphine blocks epsilon- and micro-opioid receptor-mediated antinociception in the mouse.
Mizoguchi H; Spaulding A; Leitermann R; Wu HE; Nagase H; Tseng LF
J Pharmacol Exp Ther; 2003 Jul; 306(1):394-400. PubMed ID: 12721333
[TBL] [Abstract][Full Text] [Related]
13. Pentazocine-induced antinociception is mediated mainly by μ-opioid receptors and compromised by κ-opioid receptors in mice.
Shu H; Hayashida M; Arita H; Huang W; Zhang H; An K; Wu G; Hanaoka K
J Pharmacol Exp Ther; 2011 Aug; 338(2):579-87. PubMed ID: 21543510
[TBL] [Abstract][Full Text] [Related]
14. Intracerebroventricular administration of CYX-6, a potent μ-opioid receptor agonist, a δ- and κ-opioid receptor antagonist and a biased ligand at μ, δ & κ-opioid receptors, evokes antinociception with minimal constipation and respiratory depression in rats in contrast to morphine.
Imam MZ; Kuo A; Ghassabian S; Cai Y; Qin Y; Li T; Smith MT
Eur J Pharmacol; 2020 Mar; 871():172918. PubMed ID: 31958457
[TBL] [Abstract][Full Text] [Related]
15. Pharmacological mechanisms underlying the antinociceptive and tolerance effects of the 6,14-bridged oripavine compound 030418.
Wen Q; Yu G; Li YL; Yan LD; Gong ZH
Acta Pharmacol Sin; 2011 Oct; 32(10):1215-24. PubMed ID: 21863064
[TBL] [Abstract][Full Text] [Related]
16. Anti-nociception mediated by a κ opioid receptor agonist is blocked by a δ receptor agonist.
Taylor AM; Roberts KW; Pradhan AA; Akbari HA; Walwyn W; Lutfy K; Carroll FI; Cahill CM; Evans CJ
Br J Pharmacol; 2015 Jan; 172(2):691-703. PubMed ID: 24923251
[TBL] [Abstract][Full Text] [Related]
17. Thienorphine is a potent long-acting partial opioid agonist: a comparative study with buprenorphine.
Yu G; Yue YJ; Cui MX; Gong ZH
J Pharmacol Exp Ther; 2006 Jul; 318(1):282-7. PubMed ID: 16569757
[TBL] [Abstract][Full Text] [Related]
18. Neurofilament proteins and cAMP pathway in brains of mu-, delta- or kappa-opioid receptor gene knock-out mice: effects of chronic morphine administration.
García-Sevilla JA; Ferrer-Alcón M; Martín M; Kieffer BL; Maldonado R
Neuropharmacology; 2004 Mar; 46(4):519-30. PubMed ID: 14975676
[TBL] [Abstract][Full Text] [Related]
19. Buprenorphine-induced antinociception is mediated by mu-opioid receptors and compromised by concomitant activation of opioid receptor-like receptors.
Lutfy K; Eitan S; Bryant CD; Yang YC; Saliminejad N; Walwyn W; Kieffer BL; Takeshima H; Carroll FI; Maidment NT; Evans CJ
J Neurosci; 2003 Nov; 23(32):10331-7. PubMed ID: 14614092
[TBL] [Abstract][Full Text] [Related]
20. In vivo pharmacological characterization of SoRI 9409, a nonpeptidic opioid mu-agonist/delta-antagonist that produces limited antinociceptive tolerance and attenuates morphine physical dependence.
Wells JL; Bartlett JL; Ananthan S; Bilsky EJ
J Pharmacol Exp Ther; 2001 May; 297(2):597-605. PubMed ID: 11303048
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
